Compare OTEX & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OTEX | ASND |
|---|---|---|
| Founded | 1991 | 2006 |
| Country | Canada | Denmark |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 17.1B |
| IPO Year | 1998 | 2014 |
| Metric | OTEX | ASND |
|---|---|---|
| Price | $23.70 | $271.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 21 |
| Target Price | $28.14 | ★ $315.14 |
| AVG Volume (30 Days) | ★ 1.2M | 591.6K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | ★ 4.69% | N/A |
| EPS Growth | ★ 56.36 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $2,815,241,000.00 | N/A |
| Revenue This Year | N/A | $91.55 |
| Revenue Next Year | $1.67 | $46.52 |
| P/E Ratio | $37.28 | ★ N/A |
| Revenue Growth | ★ 22.88 | N/A |
| 52 Week Low | $19.78 | $188.08 |
| 52 Week High | $34.10 | $282.15 |
| Indicator | OTEX | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 36.22 | 66.66 |
| Support Level | $23.38 | $214.93 |
| Resistance Level | $23.71 | $272.47 |
| Average True Range (ATR) | 0.66 | 7.53 |
| MACD | -0.34 | 1.57 |
| Stochastic Oscillator | 2.74 | 70.63 |
Open Text Corp provides data management for enterprise AI, offering a secure data foundation and trusted context for credible AI outcomes across private, public, and sovereign cloud, managed cloud services, API, and on-premises environments. The Company also provides cybersecurity solutions to protect sensitive data, applications and systems across complex hybrid environments, including identity and access management, threat detection and response, data protection and application security. It serves private, public, and regulated sectors, including retail, financial services, government, manufacturing, healthcare, energy, and logistics, with clients. Geographically, it derives maximum revenue from the Americas.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.